Early albuminuria reduction with finerenone (Kerendia) drove protection against chronic kidney disease (CKD) progression in people with type 2 diabetes, according to a post-hoc mediation analysis. At ...

WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA ® (finerenone) significantly reduced urine ...

Please provide your email address to receive an email when new articles are posted on . Finerenone reduced risk for CV death and worsening heart failure vs. placebo in this patient population. Pooled ...

Researchers from National Taiwan University Hospital and collaborating institutions have demonstrated that finerenone, a new-generation nonsteroidal mineralocorticoid receptor antagonist (MRA), ...

Finerenone use in trial patients with HFpEF or HFmrEF increased hyperkalemia risk, especially in those with CKD. Finerenone use in patients with heart failure and preserved or mildly reduced ejection ...

The FINEARTS-HF study included 46% women, showing finerenone's efficacy in reducing cardiovascular events in HFmrEF/HFpEF patients, with similar benefits for both genders. Win statistics offered a ...

Compared with monotherapy, finerenone plus empagliflozin was associated with improved kidney outcomes in T2D and CKD regardless of GLP-1RA use. Compared with monotherapy and regardless of prior ...

(RTTNews) - Bayer announced that the FDA has approved finerenone or Kerendia for the treatment of adult patients with heart failure and a left ventricular ejection fraction of greater than or equal to ...

About The Study: In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, resulted in more frequent ...

Data to be presented include two subgroup analyses from the pivotal Phase III FINEARTS-HF trial, which assessed the safety and efficacy of finerenone versus placebo in heart failure (HF) patients with ...